Chemotherapy may benefit men with penile cancer.
The nonrandomized phase II study included men with stage III or stage IV penile squamous cell carcinoma and affected regional lymph nodes, but without distant metastases. Out of 30 men, half of the patients had either a partial or complete response, and 36.7% remained free from recurrence at the last clinical assessment. The patients were able to tolerate the chemotherapy at full doses and on schedule, and 76.7% received all four scheduled courses.
Pagliaro, L.C., Williams, D.L., Daliani, D., Williams, M.B., Osai, W., Kincaid, M., ... Pettaway, C.A. (2010). Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: A phase II study. Journal of Clinical Oncology, 28, 3851-3857. doi: 10.1200/JCO.2010.29.5477
[By Deborah McBride, RN, MSN, CPON[R], Contributing Editor]
|Printer friendly Cite/link Email Feedback|
|Article Type:||Brief article|
|Date:||Dec 1, 2010|
|Previous Article:||Obesity is a difficult subject for patients and nurses.|
|Next Article:||HT may increase breast cancer risk in women with dense breasts.|